-DOCSTART- -X- O
The -X- _ O
arthropod-transmitted -X- _ O
chikungunya -X- _ O
virus -X- _ O
( -X- _ O
CHIKV -X- _ O
) -X- _ O
causes -X- _ O
a -X- _ O
flu-like -X- _ O
disease -X- _ O
that -X- _ O
is -X- _ O
characterized -X- _ O
by -X- _ O
incapacitating -X- _ O
arthralgia. -X- _ O
The -X- _ O
re-emergence -X- _ O
of -X- _ O
CHIKV -X- _ O
and -X- _ O
the -X- _ O
continual -X- _ O
risk -X- _ O
of -X- _ O
new -X- _ O
epidemics -X- _ O
have -X- _ O
reignited -X- _ O
research -X- _ O
in -X- _ O
CHIKV -X- _ O
pathogenesis. -X- _ O
Virus-specific -X- _ O
antibodies -X- _ O
have -X- _ O
been -X- _ O
shown -X- _ O
to -X- _ O
control -X- _ O
virus -X- _ O
clearance -X- _ O
, -X- _ O
but -X- _ O
antibodies -X- _ O
present -X- _ O
at -X- _ O
sub-neutralizing -X- _ O
concentrations -X- _ O
can -X- _ O
also -X- _ O
augment -X- _ O
virus -X- _ O
infection -X- _ O
that -X- _ O
exacerbates -X- _ O
disease -X- _ O
severity. -X- _ O
To -X- _ O
explore -X- _ O
this -X- _ O
occurrence -X- _ O
, -X- _ O
CHIKV -X- _ O
infection -X- _ O
was -X- _ O
investigated -X- _ O
in -X- _ O
the -X- _ O
presence -X- _ O
of -X- _ O
CHIKV-specific -X- _ B-Intervention
antibodies -X- _ I-Intervention
in -X- _ O
both -X- _ O
primary -X- _ B-Patient
human -X- _ I-Patient
cells -X- _ I-Patient
and -X- _ O
a -X- _ O
murine -X- _ B-Comparison
macrophage -X- _ I-Comparison
cell -X- _ I-Comparison
line -X- _ I-Comparison
, -X- _ I-Comparison
RAW264.7. -X- _ I-Comparison
Enhanced -X- _ B-Outcome
attachment -X- _ I-Outcome
of -X- _ I-Outcome
CHIKV -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
primary -X- _ I-Outcome
human -X- _ I-Outcome
monocytes -X- _ I-Outcome
and -X- _ I-Outcome
B -X- _ I-Outcome
cells -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
while -X- _ I-Outcome
increased -X- _ I-Outcome
viral -X- _ I-Outcome
replication -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
RAW264.7 -X- _ I-Outcome
cells. -X- _ I-Outcome
Blocking -X- _ O
of -X- _ O
specific -X- _ O
Fc -X- _ O
receptors -X- _ O
( -X- _ O
FcÎ³Rs -X- _ O
) -X- _ O
led -X- _ O
to -X- _ O
the -X- _ O
abrogation -X- _ O
of -X- _ O
these -X- _ O
observations. -X- _ O
Furthermore -X- _ O
, -X- _ O
experimental -X- _ O
infection -X- _ O
in -X- _ O
adult -X- _ O
mice -X- _ O
showed -X- _ O
that -X- _ O
animals -X- _ B-Outcome
had -X- _ I-Outcome
higher -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
loads -X- _ I-Outcome
and -X- _ I-Outcome
endured -X- _ I-Outcome
more -X- _ I-Outcome
severe -X- _ I-Outcome
joint -X- _ I-Outcome
inflammation -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
presence -X- _ I-Outcome
of -X- _ I-Outcome
sub-neutralizing -X- _ I-Outcome
concentrations -X- _ I-Outcome
of -X- _ I-Outcome
CHIKV-specific -X- _ I-Outcome
antibodies. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
, -X- _ O
CHIKV -X- _ B-Outcome
infection -X- _ I-Outcome
in -X- _ I-Outcome
11 -X- _ I-Outcome
days -X- _ I-Outcome
old -X- _ I-Outcome
mice -X- _ I-Outcome
under -X- _ I-Outcome
enhancing -X- _ I-Outcome
condition -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
higher -X- _ I-Outcome
muscles -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
load -X- _ I-Outcome
detected -X- _ I-Outcome
and -X- _ I-Outcome
death. -X- _ I-Outcome
These -X- _ O
observations -X- _ O
provide -X- _ O
the -X- _ O
first -X- _ O
evidence -X- _ O
of -X- _ O
antibody-mediated -X- _ O
enhancement -X- _ O
in -X- _ O
CHIKV -X- _ O
infection -X- _ O
and -X- _ O
pathogenesis -X- _ O
and -X- _ O
could -X- _ O
also -X- _ O
be -X- _ O
relevant -X- _ O
for -X- _ O
other -X- _ O
important -X- _ O
arboviruses -X- _ O
such -X- _ O
as -X- _ O
Zika -X- _ O
virus -X- _ O
. -X- _ O

